BioClinica and Kinapse Partner to Accelerate RBM Implementation
News May 28, 2015
BioClinica®, Inc. has announced that it has partnered with Kinapse to accelerate Risk-Based Monitoring (RBM) implementation on global clinical trials using BioClinica's Compass Intelligent Monitoring solution.
"Implementing a comprehensive RBM solution can make a real difference in clinical research," BioClinica CEO John Hubbard said. "We're excited about this collaboration as it helps move the industry forward with intelligent monitoring by bringing together our technology and subject matter expertise with Kinapse's broad implementation experience."
Kinapse employs 450 professionals globally and has more than ten years of experience providing strategy and operations consultancy and capability-building programs, including RBM, to life sciences companies.
"In evaluating RBM-enabling technologies, we found BioClinica's Compass provides one of the most comprehensive solutions," said Stuart Donald, vice president of advisory services of Kinapse. "Compass is uniquely designed for RBM and has a rich tool set to solve risk and quality issues, making it the right technology in this new era of monitoring."
Kinapse's role includes easing the change management process as organizations transition to RBM. "We manage implementation from start to finish, including development of supporting processes," Donald said.
The partnership comes at a time of increasing demand for Compass and as several pilot studies using the technology show significant improvement in quality and risk reduction. BioClinica's Vice President of Clinical Innovation, Courtney McBean explained, "Compass catches issues that often go overlooked by onsite monitoring until later in the trial. Finding and fixing issues sooner is less costly and less risky than dealing with bigger problems down the road, especially when it comes to quality and safety."
BioClinica and Kinapse will make a joint presentation, Essential Steps to Successful Risk-Based Monitoring, on June 4 in Tokyo, Japan.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE